CHEK2 and breast carcinoma: According to the NCCN guidelines v2.2024 (27 September 2023), germline PVs in the genes ATM, BARD1, RAD51C, RAD51D, NF1, and CHEK2 confer an absolute breast cancer risk between 17% and 40%.